Brilaroxazine
Cat. No.：YN320402
CAS No. ：1239729-06-6
| 产品名称: | Brilaroxazine |
| CAS No.: | 1239729-06-6 |
| Chemical Name: | 6-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]-2H-benzo[b][1,4]oxazin-3(4H)-one; 6-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-2H-1,4-benzoxazin-3(4H)-one; RP 5063; |
| Synonyms: | RP5063 |
| 分子量: | 450.36 |
| 分子式: | C₂₂H₂₅Cl₂N₃O₃ |
| SMILES: | O=C1NC2=CC(OCCCCN3CCN(C(C=CC=C4Cl)=C4Cl)CC3)=CC=C2OC1 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Brilaroxazine (RP5603) 是一种有效的具有口服活性的多巴胺/5-羟色胺 (dopamine (DA)/5-HT) 调节剂。Brilaroxazine 是多巴胺 (DA) D2，D3 和 D4 受体，血清素 5-HT1A (Ki=1.5 nM) 和 5-HT2A (Ki=2.5 nM) 的部分激动剂，对 5-HT2B (Ki=0.19 nM) 和 5-HT7 (Ki=2.7 nM) 受体具有拮抗剂活性。Brilaroxazine 是一种非典型抗精神病试剂，在动物模型中，具有改善神经精神病 |
| IC50和靶点: | [{name:"5-HT1A Receptor:1.5 nM (Ki)"},{name: "5-HT2A Receptor:2.5 nM (Ki)"},{name: "5-HT2B Receptor:0.19 nM (Ki)"},{name: "5-HT7 Receptor:2.7 nM (Ki)'}, 'D2 Receptor', 'D3 Receptor', 'D4 Receptor'] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Köster, L., et al.: Expert. Opin. Emerg. Drugs., 19, 511-531 (2014)
